Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)


CAMBRIDGE, Mass., Sept. 22, 2022–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on treating serious diseases in which protein growth factors play a fundamental role, announced today that the Company made stock awards as a material incentive to an employee hired by Scholar Rock in September 2022.

The plan, approved by the Company’s Board of Directors on June 16, 2022, is solely for the purpose of granting stock awards to individuals who were not previously employees of Scholar Rock, or after a period of good faith non-employment, as an incentive material for such persons who take up employment with Scholar Rock, in accordance with Nasdaq Listing Rule 5635(c)(4).

Jay Backstrom, MD, MPH was granted a stock option on September 20, 2022 (the “Grant Date”) to purchase an aggregate of 1,000,000 common shares of the Company at an exercise price of $8.85 per share. The stock option award vests in respect of 25% of the common shares underlying the award on the first anniversary of the grant date and the remaining 75% of the common shares underlying the stock option award vest in 12 equal installments thereafter, subject to Dr . Backstrom’s continued service to the Company through the applicable exercise date.

READ:  Alliance Française de Newport  names Michael Warren its new President

About Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which protein growth factor signaling plays a fundamental role. Scholar Rock is building a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a variety of devastating diseases, including neuromuscular disorders, cancer and fibrosis. Scholar Rock’s approach of targeting the molecular mechanisms of growth factor activation enabled the company to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes that its focus on biologically validated growth factors could enable a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

READ:  The New York Institute of Finance (NYIF) Announces Global Partnership With Rock Orient Foundation and the American Education Center Inc.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Availability of more information about Scholar Rock

Investors and others should note that we communicate with our investors and the public through our corporate website www.scholarrock.com, including but not limited to corporate disclosures, investor presentations and FAQs, filings with the Securities and Exchange Commission, press releases, public conference transcripts and webcast logs, as well as on Twitter and LinkedIn. The information we publish on our website or on Twitter or LinkedIn could be considered material information. As such, we encourage investors, the media and other interested parties to regularly review the information we post there. Nothing on our website or social media will be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended.

READ:  Tyson heir CFO pick draws ethical fire

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005757/en/

contacts

Scholar Rock:

investors
Rushmie Nofsinger
Scholar Rock
[email protected]
[email protected]
857-259-5573

media
Ariane Lovel
Finnish partners
[email protected]
[email protected]
917-565-2204





Source link